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OBJECTIVE—Macrophages play an important role in the patho-
genesis of insulin resistance via the production of proinﬂamma-
tory cytokines. Our goal is to decipher the molecular linkage
between proinﬂammatory cytokine production and insulin resis-
tance in macrophages.
RESEARCH DESIGN AND METHODS—We determined cyto-
kine proﬁles in cultured macrophages and identiﬁed interleukin
(IL)-1 gene as a potential target of FoxO1, a key transcription
factor that mediates insulin action on gene expression. We
studied the mechanism by which FoxO1 mediates insulin-depen-
dent regulation of IL-1 expression in cultured macrophages and
correlated FoxO1 activity in peritoneal macrophages with IL-1
production proﬁles in mice with low-grade inﬂammation or
insulin resistance.
RESULTS—FoxO1 selectively promoted IL-1 production in
cultured macrophages. This effect correlated with the ability of
FoxO1 to bind and enhance IL-1 promoter activity. Mutations of
the FoxO1 binding site within the IL-1 promoter abolished
FoxO1 induction of IL-1 expression. Macrophages from insulin-
resistant obese db/db mice or lipopolysaccharide-inﬂicted mice
were associated with increased FoxO1 production, correlating
with elevated levels of IL-1 mRNA in macrophages and IL-1
protein in plasma. In nonstimulated macrophages, FoxO1 re-
mained inert with benign effects on IL-1 expression. In response
to inﬂammatory stimuli, FoxO1 activity was augmented because
of an impaired ability of insulin to phosphorylate FoxO1 and
promote its nuclear exclusion. This effect along with nuclear
factor-B acted to stimulate IL-1 production in activated
macrophages.
CONCLUSIONS—FoxO1 signaling through nuclear factor-B
plays an important role in coupling proinﬂammatory cytokine
production to insulin resistance in obesity and diabetes.
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ow-grade inﬂammation and insulin resistance are
two key components that are interwoven in con-
trol subjects with obesity and type 2 diabetes.
The former is accompanied by markedly elevated
production of proinﬂammatory cytokines in the body,
whereas the latter is characterized by signiﬁcantly dimin-
ished responsiveness of peripheral tissues to normal
plasma insulin levels. Although there is a lack of consen-
sus regarding the cause-and-effect relationship between
chronic exposure to low-grade inﬂammation and onset of
insulin resistance, the intangible association between these
two pathological traits forebodes a cross-talking mecha-
nism that integrates abnormal production of inﬂammatory
cytokines to the development of insulin resistance in obesity
and type 2 diabetes (1–5). Indeed, amelioration of insulin
resistance with insulin sensitizers is associated with re-
duction of inﬂammation in obesity and type 2 diabetes
(6–9). Likewise, anti-inﬂammatory therapies result in im-
proved insulin sensitivity in subjects with chronic inﬂam-
mation (10–13). Insulin exerts an independent inhibitory
effect on proinﬂammatory cytokine production in human
aortic endothelial cells and mononuclear cells of obese
control subjects (14–16).
Crucial for proinﬂammatory cytokine production are
macrophages, a cell type that is differentiated from mono-
cytes in response to inﬂammatory stimuli. Rampant mac-
rophage inﬁltration into peripheral tissues such as liver
and adipose tissues are seen in human subjects with
metabolic syndrome as well as in animal models of obesity
and type 2 diabetes (17–22). These tissue-resident macro-
phages play important roles in instigating insulin resis-
tance by promoting the production of proinﬂammatory
cytokines (17,23,24). Nonetheless, the molecular basis
linking insulin resistance to increased proinﬂammatory
cytokine production remains incompletely understood.
Among proinﬂammatory cytokines that are detrimental
to insulin signaling are interleukin-1 (IL-1), interleukin-6
(IL-6), tumor necrosis factor- (TNF-), and interferon-
(IFN-). These proinﬂammatory cytokines act in an auto-
crine or paracrine manner to interfere with insulin signal-
ing in peripheral tissues and macrophages (1–3). In an
attempt to decipher the molecular link between abnormal
proinﬂammatory production and insulin resistance, we
determined the effect of FoxO1 on cytokine production
proﬁles in cultured macrophages. FoxO1 is a forkhead
transcriptional factor that acts to mediate insulin action on
target gene expression in peripheral cells (25–27). Inap-
propriately increased FoxO1 activity, resulting from impaired
insulin signaling, is associated with altered metabolism in
obesity and type 2 diabetes (28–30). We show that FoxO1
selectively stimulated macrophage production of IL-1,a
prominent proinﬂammatory cytokine whose overproduc-
tion exerts a deleterious effect on peripheral insulin sig-
naling and -cell function (31–33). Increased macrophage
IL-1 production is closely associated with insulin resis-
tance in obesity and type 2 diabetes (31,34). There is
clinical evidence that blockage of IL-1 signaling via its
receptor antagonist contributes signiﬁcantly to improved
insulin sensitivity in subjects with type 2 diabetes (31).
Likewise, administration of neutralizing IL-1 antibodies
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mice (34). These data together with our observations
spur the hypothesis that FoxO1 plays a signiﬁcant role
in linking proinﬂammatory cytokine IL-1 production to
insulin resistance.
In this study, we addressed this hypothesis in cultured
macrophages as well as in normal mice with lipopolysac-
charide (LPS)-elicited inﬂammation and obese db/db mice
with insulin resistance. We show that FoxO1 was capable
of binding to the IL-1 promoter, augmenting IL-1 pro-
moter activity. This effect contributed to increased IL-1
expression and was counteracted by insulin. Mutations
of the FoxO1 target site within the IL-1 promoter abol-
ished FoxO1-mediated induction of IL-1 expression.
Under inﬂammatory conditions, FoxO1 expression was
upregulated, correlating with increased production of
IL-1 protein in cultured macrophages. Furthermore, in-
creased FoxO1 activity along with marked upregulation
of IL-1 production was detectable in peritoneal macro-
phages of normal mice with prior exposure to LPS and
insulin-resistant mice with genetic predisposition to obe-
sity. Intriguingly, FoxO1 remained inert with benign effects
on IL-1 expression in the absence of inﬂammatory cues.
In response to inﬂammation, FoxO1 activity was aug-
mented along with the activation of nuclear factor (NF)-
B, which in turn acted with FoxO1 in a synergistic
manner to promote IL-1 overproduction in macrophages.
While unrestrained IL-1 production is associated with
impaired insulin action in the face of chronic low-grade
inﬂammation (1,31,34), the underlying mechanism remains
elusive. Our data underscore the importance of FoxO1 in
regulating macrophage production of IL-1, suggesting
that FoxO1 signaling through NF-B plays a signiﬁcant
role in coupling proinﬂammatory cytokine production to
insulin resistance in obesity and type 2 diabetes.
RESEARCH DESIGN AND METHODS
Male homozygous db/db and age- or sex-matched heterozygous littermates
db/ were obtained from the Jackson Laboratory (Bar Harbor, MI). Male
Balb/c mice were purchased from Charles River Laboratories (Wilmington,
MA). Mice were housed in standard shoebox cages supplied with standard rat
diet and water ad libitum in a pathogen-free facility with a 12-h light/dark
cycle. For LPS treatment, male Balb/c mice (25 g) were injected intraperi-
toneally with LPS at the dose of 4 mg/kg body weight for 2 consecutive days,
as described (35). To isolate peritoneal macrophages, mice were killed and
peritoneal lavage ﬂuid was collected by washing the peritoneum with 5-ml
ice-cold Hank’s balanced salt solution (HBSS; Gibco, Carlsbad, CA). Subse-
quent preparation of peritoneal macrophages was according to the protocol as
described (35). All procedures were approved by the Institutional Animal Care
and Usage Committee of Children’s Hospital of Pittsburgh. Other methods
including the statistics are described in the supplemental materials available
in an online appendix at http://diabetes.diabetesjournals.org/cgi/full/db09-
0232/DC1.
RESULTS
Effect of FoxO1 on cytokine production in cultured
macrophages. Aberrant proinﬂammatory cytokine pro-
duction is intertwined with insulin resistance in obesity
and type 2 diabetes. To decipher the molecular basis that
links proinﬂammatory cytokine production to insulin re-
sistance, we determined the effect of FoxO1 on cytokine
production in macrophages, a cell type that plays a pivotal
role in mediating whole-body insulin resistance in the face
of low-grade inﬂammation. Macrophage RAW264.7 cells
were transduced with Adv-FoxO1 or Adv-null vector at a
predeﬁned MOI (200 pfu/cell), followed by the determina-
tion of cytokine concentrations in conditioned medium. As
shown in Fig. 1, transduction of RAW264.7 cells by FoxO1
vector resulted in a signiﬁcant induction of IL-1 and IL-2
production without alterations in the production of other
cytokines including IL-4, IL-5, IL-6, IL-12, IFN-, TNF-,
and granulocyte monocyte colony-stimulating factor. In
contrast, IL-10 expression was signiﬁcantly downregulated
in response to FoxO1 production in RAW264.7 cells. In the
absence of LPS, the expression of proinﬂammatory cyto-
kines remained at low basal levels independently of FoxO1
action (supplemental Table S1). These data underscore
the importance of FoxO1 in regulating cytokine produc-
tion in LPS-activated macrophages. Because of the close
association between abnormal production of IL-1 in
macrophages and the pathogenesis of insulin resistance,
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FIG. 1. Effect of FoxO1 on cytokine production proﬁles in cultured macrophages. RAW264.7 cells were mock-treated with PBS, or transduced with
Adv-FoxO1 or control Adv-null vector at a ﬁxed dose (MOI, 200 pfu/cell). After 24-h incubation in the presence of 100 ng/ml LPS, conditioned
medium was harvested for proﬁling the production of cytokine IL-1 (A), IL-2 (B), IL-4 (C), IL-5 (D), IL-6 (E), IL-10 (F), IL-12 (G), IFN- (H),
TNF- (I), and granulocyte monocyte colony-stimulating factor (GM-CSF) (J). Data were obtained from three independent experiments. *P <
0.001 vs. controls.
D. SU AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 58, NOVEMBER 2009 2625we focused on the delineation of the molecular basis
underlying FoxO1-mediated induction of IL-1 in this
study.
Impact of FoxO1 on IL-1 production in peritoneal
macrophages in LPS-treated mice. To investigate the
potential role of FoxO1 in macrophage production of IL-1
in vivo, we treated Balb/C mice with once-daily intraperi-
toneal administration of LPS (4 mg/kg) for 2 days. This
treatment elicited acute inﬂammation in mice. Compared
to PBS-treated control mice (n  8), LPS-treated mice
(n  8) exhibited signiﬁcantly elevated plasma IL-1 levels
(Fig. 2A). Two days after LPS treatment, mice were killed
and peritoneal macrophages were retrieved for real-time
qRT-PCR analysis. LPS treatment resulted in a signiﬁcant
induction of FoxO1 expression (Fig. 2B), correlating with
signiﬁcantly elevated IL-1 mRNA levels in peritoneal
macrophages (Fig. 2C).
FoxO1 and IL-1 expression in peritoneal macro-
phages in obese db/db mice. To determine whether
FoxO1 plays a role in linking insulin resistance to aberrant
IL-1 expression, we studied FoxO1 expression in perito-
neal macrophages in obese db/db mice. Because of the
lack of leptin receptor, db/db mice are genetically obese,
developing insulin resistance and hyperinsulinemia at
weaning. Two groups of male db/db mice (n  7, male, 10
weeks old) and age- or sex-matched heterozygous db/
lean littermates (n  7) were fasted for 16 h, as described
(30). Peritoneal macrophages were isolated from individ-
ual mice and subjected to real-time qRT-PCR analysis. As
shown in Fig. 3A, FoxO1 expression was signiﬁcantly
upregulated in peritoneal macrophages of insulin-resistant
obese db/db mice. Furthermore, db/db mice were associ-
ated with signiﬁcantly higher levels of IL-1 mRNA in
peritoneal macrophages (Fig. 3B) and IL-1 protein in
plasma (Fig. 3C), which was indicative of chronic inﬂam-
mation in insulin-resistant obese db/db mice.
Effect of FoxO1 on IL-1 expression in macrophages.
We hypothesized that the IL-1 gene is a FoxO1 target, and
FoxO1 promotes IL-1 expression in macrophages in
response to inﬂammation. To test this hypothesis, we
treated RAW264.7 cells with palmitate, the predominant
saturated form of free fatty acid that is known to elicit
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FIG. 2. FoxO1 expression is upregulated in peritoneal macrophages of
LPS-treated mice. Male Balb/C mice (8 weeks old, n  8 per group)
were treated with once-daily intraperitoneal injection of LPS (4 mg/kg
body weight) or mock-treated with PBS for 2 days. Aliquots of blood
(50 l) were sampled from the tail vein for the determination of plasma
IL-1 levels (A). Two days after LPS treatment, peritoneal macro-
phages were isolated from individual mice for the preparation of total
RNA, which was subjected to real-time qRT-PCR assay for the deter-
mination of FoxO1 (B) and IL-1 (C) mRNA levels using 18S rRNA as
control. *P < 0.05 and **P < 0.001 vs. control.
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FIG. 3. Covariation of FoxO1 and IL-1 expression in peritoneal
macrophages of insulin-resistant db/db mice. Peritoneal macrophages
were isolated from insulin-resistant obese db/db mice (n  7) and
control db/ littermates (n  7). Total macrophage RNA was prepared
and subjected to real-time qRT-PCR assay for the determination of
FoxO1 (A) and IL-1 (B) mRNA levels. Plasma IL-1 levels were
determined by anti–IL-1 ELISA (C). *P < 0.05 vs. control.
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resulted in signiﬁcant induction of IL-1 production, as
reﬂected in markedly elevated levels of IL-1 protein in
conditioned medium and IL-1 mRNA in cells. This effect
was accompanied by signiﬁcantly increased FoxO1 ex-
pression in palmitate-treated macrophages.
Mechanism of FoxO1-mediated induction of IL-1
expression. To characterize the underlying mechanism,
we addressed whether FoxO1 targets the IL-1 promoter
for trans-activation. A 2-kb DNA fragment harboring the
mouse IL-1 promoter was cloned into the pGL3-Basic
luciferase reporter system (Fig. 5A). The resulting plasmid
pHD386 encoding the IL-1 promoter–directed luciferase
was transfected via electroporation into RAW264.7 cells.
IL-1 promoter activity was determined in response to ad-
enovirus-mediated FoxO1 production in the presence
and absence of insulin. As shown in Fig. 5B, we detected
a more than sixfold induction of the IL-1 promoter
activity in RAW264.7 cells that were pretransduced with
FoxO1 vector. This effect was counteracted by insulin,
correlating with the ability of FoxO1 to undergo insulin-
dependent translocation from the nucleus to cytoplasm
(25,27).
To corroborate these ﬁndings, we altered the insulin-
responsive element (IRE) motif within the IL-1 promoter
via site-directed mutagenesis (supplemental Fig. S1). The
resulting mutant IL-1 promoter was analyzed for its
ability to mediate the stimulatory effect of FoxO1 on IL-1
expression. As shown in Fig. 5C, alterations within the IRE
DNA motif rendered the mutant IL-1 promoter unrespon-
sive to FoxO1 production in RAW264.7 cells. As control,
adenovirus-mediated FoxO1 production resulted in a sig-
niﬁcant induction of wild-type IL-1 promoter activity
(Fig. 5C).
Effect of FoxO1 knockdown on IL-1 expression. To
further prove that FoxO1 contributed to IL-1 regulation,
we employed an RNA interference (RNAi)-mediated gene
silencing approach to knockdown FoxO1 expression in
cultured macrophages. RAW264.7 cells were transfected
with pHD386 expressing the IL-1 promoter-directed lu-
ciferase reporter gene, followed by transduction of adeno-
viral vectors expressing FoxO1-speciﬁc RNAi or control
scrambled RNAi, as described (30). After 24-h incubation,
cells were subjected to luciferase activity assay. As shown
in Fig. 5D, RNAi-mediated FoxO1 knockdown resulted in
abolition of FoxO1-mediated induction of IL- promoter
activity in LPS-stimulated RAW264.7 cells. These results
were corroborated when the conditioned medium was
used for the determination of IL-1 protein. As shown in
Fig. 5E, medium IL-1 concentration was markedly in-
duced by FoxO1. This effect was abolished by RNAi-
mediated FoxO1 knockdown, as reﬂected in 80% of
reduction in FoxO1 protein levels in RAW264.7 cells that
were pretransduced with FoxO1-RNAi vector (Fig. 5F).
Molecular interaction of FoxO1 with IL-1 promoter
DNA. The above results spurred the idea that FoxO1
stimulates IL-1 expression via direct binding to the IL-1
promoter. Consistent with this idea, the IL-1 promoter
contains an IRE (Fig. 5A), a consensus DNA motif that is
responsible for binding and mediating FoxO1 induction of
target gene expression (25,27). Interestingly, similar
FoxO1 consensus sites were detected in the regulatory
region of both human and rat IL-1 promoters, suggesting
an evolutionally conserved mechanism (supplemental Fig.
S2). To determine the ability of the conserved IRE motif to
mediate the stimulatory effect of FoxO1 on IL-1 promoter
activity, we performed chromatin immunoprecipitation
(ChIP) assay to analyze the potential interaction of FoxO1
with IL-1 promoter DNA in RAW264.7 cells. Because of
low FoxO1 expression in unstimulated RAW264.7 cells, we
transduced RAW264.7 cells with FoxO1 vector in the
presence of LPS (100 ng/ml) in culture medium. After 24-h
incubation, cells were subjected to ChIP assay using rabbit
anti-FoxO1 antibody or control rabbit IgG. The resulting
immunoprecipitates were subjected to PCR analysis, using
primers ﬂanking the IRE motif within the IL-1 promoter.
A 457-bp DNA corresponding to the IRE region (1,359/
902 nt) of the IL-1 promoter was produced from
anti-FoxO1 immunoprecipitates (Fig. 5F). In contrast, the
immunoprecipitates derived from control IgG were nega-
tive in the same PCR assay.
Effect of LPS or palmitate treatment on insulin sig-
naling in macrophages. To further illustrate the role of
FoxO1 in linking aberrant IL-1 production to insulin
resistance, we determined the effect of LPS or palmitate
treatment on insulin signaling in cultured macrophages.
RAW264.7 cells were incubated in the presence of LPS
(100 ng/ml) or palmitate (0.2 mmol/l) for 36 h, followed by
the addition of insulin (300 nmol/l) into culture medium.
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FIG. 4. FoxO1 expression in palmitate-treated macrophages.
RAW264.7 cells were incubated in culture medium in the presence of
0.2 mmol/l palmitate or BSA as control for 24 h. Cells were harvested
and subjected to real-time qRT-PCR assay for the determination of
FoxO1 (A) and IL-1 (B) mRNA levels. Conditioned medium was used
for the determination of IL-1 concentrations by anti–IL-1 ELISA
(C). *P < 0.05 vs. control.
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our preliminary studies and data in the literature (36).
Cells were harvested 45 min after insulin action for the
determination of insulin-stimulated phosphorylation of
insulin receptor substrates (IRSs) and FoxO1, both of
which are key signaling molecules downstream of insulin
action. Compared to mock-treated controls, RAW264.7
cells pretreated with LPS or palmitate treatment were
associated with a signiﬁcant reduction in insulin-stimu-
lated phosphorylation of IRS2 (Fig. 6A). Because of ex-
tremely low levels of IRS1 expression in RAW264.7 cells,
we were unable to detect insulin-stimulated phosphoryla-
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FIG. 5. Effect of FoxO1 on IL-1 promoter activity in RAW264.7 cells. A: A schematic depiction of the IL-1 promoter–directed luciferase reporter
system in pHD386. A consensus IRE DNA motif and its mutant form are indicated. B: Effect of FoxO1 on wild-type IL-1 promoter activity.
RAW264.7 cells in six-well microplates were transduced with Adv-FoxO1 or control Adv-null vectors at a ﬁxed dose (MOI, 200 pfu/cell), followed
by transfection with 1-g pHD386 plus 1-g pCA35-LacZ in the presence of 100 ng/ml LPS in culture medium. After 24-h incubation in the absence
or presence of insulin (300 nmol/l), cells were harvested for the determination of luciferase and -galactosidase activities. The relative luciferase
activity was calculated by setting the ratio of luciferase/-galactosidase activity in control cells to 1. C: Effect of FoxO1 on mutant IL-1 promoter
activity. RAW264.7 cells were transfected with wild-type (WT) or mutant (MT) IL-1 promoter–directed luciferase system in the absence or
presence of adenovirus-mediated FoxO1 production. After 24-h incubation in the presence of 100 ng/ml LPS, cells were harvested for the
determination of relative luciferase activities using -galactosidase activity as internal controls. D: Effect of FoxO1 knockdown on IL-1
promoter activity. RAW264.7 cells were cotransfected with pHD386 and pCA35-LacZ in the absence or presence of adenovirus-mediated FoxO1
production. One subset of cells was transduced with 200 MOI of Adv-FoxO1-RNAi encoding FoxO1-speciﬁc RNAi or control Adv-ScRNAi encoding
scrambled RNAi. After 24-h incubation in the presence of 100 ng/ml LPS, cells were harvested for the determination of relative luciferase
activities using -galactosidase activity as internal controls. E: Effect of FoxO1 knockdown on IL-1 production. The conditioned medium from
the experiment in D was used for the determination of IL-1 levels. F: FoxO1 protein levels. Cells obtained from the experiment in D were
subjected to semiquantitative immunoblot analysis for the determination of total FoxO1 protein levels, using intracellular actin protein as control. G:
Interaction of FoxO1 with IL-1 promoter DNA. RAW264.7 cells incubated in six-well dishes in the presence of LPS (100 ng/ml) for 24 h. Cells were
ﬁxed with 1% formaldehyde, followed by ChIP assay using rabbit anti-FoxO1 or control IgG (rabbit anti–-galactosidase). Immunoprecipitates were
analyzed by PCR assay for the detection of DNA, using primers ﬂanking the consensus FoxO1 binding site within the IL-1 promoter. Data in B–F were
obtained from three to ﬁve independent experiments. *P < 0.001 and
#P < 0.05 vs. control. NS, not signiﬁcant.
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(37), who show that IRS1 is undetectable and IRS2 is the
sole substrate downstream of insulin action in primary
murine macrophages. LPS or palmitate treatment also
resulted in marked elevations of FoxO1 production in
RAW264.7 cells (Fig. 6B and C). However, the ratio of
phosphorylated versus total FoxO1 levels was signiﬁcantly
reduced, reﬂecting an impaired ability of insulin to pro-
mote FoxO1 phosphorylation in LPS- or palmitate-treated
RAW264.7 cells (Fig. 6B and C).
FoxO1 signaling through NF-B stimulates IL-1
expression. Our ﬁndings of FoxO1-stimulated IL-1 pro-
duction in inﬂammation-inﬂicted macrophages pose two
potential mechanisms: 1) FoxO1 exerts an independent
effect on IL-1 production, and 2) alternatively, FoxO1
promotes IL-1 overproduction through NF-B, a well-
characterized pathway that is responsible for mediating
proinﬂammatory cytokine production in macrophages un-
der inﬂammatory or insulin-resistant conditions. To distin-
guish these two possibilities, we chose to study the impact
of FoxO1 in nonstimulated macrophages. Because of a
concomitant induction of endogenous FoxO1 and NF-B
production in LPS- or palmitate-treated macrophages, un-
stimulated RAW264.7 cells were transduced with FoxO1
or control vector to determine the net effect of FoxO1 on
IL-1 expression in the absence of NF-B activation.
Unexpectedly, FoxO1 failed to stimulate IL-1 production,
as the amount of immunoreactive IL-1 protein remained
unchanged in FoxO1 versus control vector–treated
RAW264.7 cells (Fig. 7A). Under the same condition,
adenovirus-mediated FoxO1 production resulted in signif-
icant induction of IL-1 production in RAW264.7 cells that
were pre-exposed to LPS (Fig. 1A). To ascertain this
ﬁnding, we transfected pHD386 encoding the IL-1 pro-
moter-directed luciferase reporter system into nonstimu-
lated RAW264.7 cells. No signiﬁcant induction of luciferase
activities in RAW264.7 cells was detected in basal states
(Fig. 7B), despite a threefold elevation in FoxO1 protein
levels in naïve RAW264.7 cells that were pretransduced
with FoxO1 vector (Fig. 7C).
To investigate whether FoxO1 contributes to IL-1
production via a mechanism that is dependent on NF-B,
we determined the effect of FoxO1 on IL-1 promoter
activity in the presence and absence of vector-mediated
production of P50 or P65, two subunits of NF-B. In
keeping with our earlier observations (Fig. 7A), adenovi-
rus-mediated FoxO1 production exerted little effects on
IL-1 promoter activity in nonstimulated RAW264.7 cells.
However, cotransfection of FoxO1 along with P50, but not
with P65, resulted in a signiﬁcant induction of IL-1
promoter activity (Fig. 7D). These results suggest that
FoxO1 associates with P50 in stimulating IL-1 expression
in macrophages, or, alternatively, P50 is required for the
recruitment of FoxO1 to its target site to stimulate IL-1
promoter activity.
To address the ﬁrst hypothesis, we studied the potential
association of FoxO1 with P50 using a coimmunoprecipi-
tation assay. We show that LPS, known to stimulate NF-B
activation, also promoted FoxO1 production in RAW264.7
cells (Fig. 7E). Thus, to determine the net impact of FoxO1
and P50 interaction on IL-1 expression, we chose to
perform the studies in unstimulated RAW264.7 cells with
vector-mediated production of FoxO1 and P50 proteins.
FoxO1-expressing RAW264.7 cells were transfected with
plasmid p50 encoding the human NF-B P50 subunit,
followed by immunoprecipitation using anti-FoxO1 or anti-
P50 antibodies. The resulting immunoprecipitates were
analyzed by immunoblot assay for FoxO1 and P50, respec-
tively. We detected the presence of FoxO1 or P50 in
immunoprecipitates that were derived from its cognate
antibody, validating the method of immunoprecipitation.
However, neither FoxO1 nor P50 was reciprocally coim-
munoprecipitated by anti-P50 or anti-FoxO1 antibodies
(data not shown). These results argue against the notion
that FoxO1 formed a complex with P50 in promoting IL-1
expression in macrophages.
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FIG. 6. Effect of LPS and palmitate on FoxO1 production in cultured
macrophages. RAW264.7 in six-well dishes were treated with either 100
ng/ml LPS or 0.2 mmol/l palmitate. Control wells of cells were mock-
treated with PBS or BSA. After 24 h of incubation, insulin (300 nmol/l)
was added to both treatment and control wells of cells. After 45-min
incubation, cells were harvested for the preparation of total cell
lysates. Aliquots of cell lyates were immunoprecipitated by anti-IRS2
antibody, followed by immunoblot assay for the determination of
phosphorylated IRS2 using antiphosphotyrosine antibody (A). In addi-
tion, aliquots of cell lysates were subjected to immunoblot analysis for
the determination of phosphorylated and total FoxO1 in response to
palmitate (B) or LPS treatment (C). Data were obtained from three
independent measurements. *P < 0.05.
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concentrations. B: RAW264.7 cells were transfected with pHD386 encoding the IL-1 promoter–directed luciferase expression system in the
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immunoblot analysis for the determination of nuclear FoxO1 protein levels. D: RAW264.7 cells were transfected with pHD386 encoding the IL-1
promoter–directed luciferase reporter in the presence of FoxO1 plus P50 or P65 production, using the dual luciferase system. After 24-h
incubation in the absence of LPS, the relative promoter activity, deﬁned as the ratio of Fireﬂy and Renilla luciferase activities, was determined.
E: Effect of LPS on FoxO1 production in RAW264.7 cells. RAW264.7 cells were incubated in the absence and presence of LPS (100 ng/ml) for 24 h,
followed by immunoblot analysis using anti-FoxO1 and anti-actin antibodies. F: Impact of NF-B P50 on interaction of FoxO1 with IL-1 promoter
DNA. RAW264.7 cells were transduced with FoxO1 vector in the presence or absence of P50 production. Control cells were either transfected with
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binding to its target site within the IL-1 promoter de-
pends on P50 in cells. Implicit in this hypothesis is the
presence of a highly conserved NF-B P50-binding site
(5	-GGGAGCATCC-3	) downstream of the IRE, the char-
acteristic DNA motif that is responsible for FoxO1 binding
(Fig. 5A). We performed ChIP assay on RAW264.7 cells in
the presence of FoxO1 or P50 expression alone or in
combination. The resulting immunoprecipitates were ana-
lyzed by semiquantitative PCR assay using speciﬁc primers
ﬂanking the FoxO1 binding site in the IL-1 promoter. As
shown in Fig. 7F, positive interactions between FoxO1 and
IL-1 promoter DNA were detected in response to FoxO1
or P50 production in RAW264.7 cells. However, coproduc-
tion of FoxO1 and P50 resulted in a synergistic effect on
FoxO1 binding to its target site within the IL-1 promoter.
This effect correlated with the costimulatory effect of
FoxO1 and P50 in combination on IL-1 promoter activity
(Fig. 7D).
Effect of siRNA-mediated P50 knockdown on macro-
phage IL-1 expression. To consolidate our ﬁndings that
FoxO1 signaling through P50 regulates IL-1 production in
macrophages, we used the siRNA-mediated gene-silencing
approach to knockdown P50 expression, followed by
determining the ability of FoxO1 to stimulate IL-1 expres-
sion in LPS-stimulated RAW264.7 cells. As shown in Fig.
7G, adenovirus-mediated FoxO1 production resulted in a
marked induction of luciferase activity, which was signif-
icantly reduced after siRNA-mediated P50 knockdown in
LPS-stimulated RAW264.7 cells. These results suggest that
depletion of NF-B P50 attenuated the ability of FoxO1 to
induce IL-1 promoter activity in macrophages.
DISCUSSION
Our goal is to understand the molecular basis that links
insulin resistance to abnormal production of proinﬂamma-
tory cytokine IL-1 in macrophages. We show that FoxO1
stimulated IL-1 production in activated macrophages. This
effect was inhibited by insulin, which is correlated with the
ability of FoxO1 to undergo insulin-dependent phosphoryla-
tion and nuclear exclusion. FoxO1 was shown to bind to the
IL-1 promoter and enhance IL-1 promoter activity. In
accordance with these observations, there is a highly con-
served FoxO1 binding site within the IL-1 promoter of
humans, rats, and mice. Mutations of the FoxO1 consensus
site abrogated FoxO1-mediated induction of IL-1 promoter
activity. In LPS- or palmitate-treated macrophages, FoxO1
expression along with its nuclear localization was increased,
contributing to augmented FoxO1 activity and elevated IL-1
production. LPS or palmitate treatment also impaired the
ability of insulin to promote IRS2 and FoxO1 phosphoryla-
tion in cultured macrophages. These data characterize
FoxO1 at the interface between abnormal production of
proinﬂammatory cytokine IL-1 and the pathogenesis of
insulin resistance in macrophages.
Macrophage production of IL-1 is governed by NF-B,
a master regulator that integrates inﬂammatory signals to
cytokine gene expression (11,38). In unstimulated cells,
NF-B is bound by IB and is sequestered in the cyto-
plasm. In the presence of inﬂammatory stimuli, IBi s
phosphorylated by IB kinase and is destined for protea-
some-mediated degradation. As a result, NF-B is dissoci-
ated from IB and is translocated to the nucleus for
promoting target gene expression (38). Consistent with
this notion is the conservation of a consensus NF-B
target site within the IL-1 promoter among different
species (supplemental Fig. S2). However, this mechanism
falls short of explaining why insulin resistance provokes
the induction of IL-1 production in activated macro-
phages. To address this fundamental issue, several inde-
pendent studies show that activation of the PI3 kinase-Akt
pathway is effective in limiting LPS-stimulated inﬂamma-
tory cytokine production with uncharacterized mecha-
nisms (39–41). Here we show that macrophage IL-1
expression is regulated by FoxO1, a key nuclear transcrip-
tional factor that mediates the inhibitory effect of insulin
on target gene expression. In the absence of insulin,
FoxO1 acts in the nucleus as an enhancer for promoting
target gene expression, whereas in the presence of insulin,
FoxO1 is phosphorylated by Akt/PKB, resulting in its
nuclear exclusion and contributing to the inhibition of
target gene expression. This phosphorylation-dependent
protein trafﬁcking mechanism is critical for insulin to
regulate FoxO1 transcriptional activity in cells (25–27,30).
Our present studies shed light on the molecular basis that
couples insulin resistance to the induction of proinﬂam-
matory cytokines. It follows that in insulin-resistant states,
loss of insulin inhibition of FoxO1 activity consequently
results in unrestrained IL-1 expression in activated mac-
rophages (Fig. 8). Consistent with this interpretation, we
show that FoxO1 activity was signiﬁcantly increased,
correlating with impaired insulin action and elevated IL-1
production in LPS- and palmitate-stimulated macrophages.
Furthermore, addition of insulin resulted in only partial
suppression of IL-1 promoter activity, which is indicative
of insulin resistance in LPS-stimulated RAW264.7 cells
(Fig. 5). Likewise, primary peritoneal macrophages re-
trieved from LPS-treated mice and insulin-resistant db/db
mice were invariably associated with increased FoxO1
activity, accompanied by elevated IL-1 levels in plasma.
Tripathy et al. (42) show that acute elevation of free fatty
acid directly provokes inﬂammation, culminating in en-
hanced NF-B activity and increased proinﬂammatory
cytokine expression in mononuclear cells in healthy indi-
viduals. These ﬁndings together with our data support the
notion that circulating mononuclear cells in insulin-
resistant obese subjects are in a proinﬂammatory state
(43). Indeed, treatment with thiazolidenediones, a class of
insulin sensitizers for improving peripheral insulin resis-
tance, reduces mononuclear NF-B activity and amelio-
rates inﬂammation in obese subjects (44–46).
Although FoxO1 targeted IL-1 promoter for trans-
activation, FoxO1 did not elicit a signiﬁcant induction of
IL-1 expression in cultured RAW264.7 cells in the ab-
sence of inﬂammatory stimuli. In response to inﬂamma-
tory signals such as LPS or palmitate treatment, FoxO1
P50-expressing plasmid alone or mock-treated. After 24-h incubation in the absence of LPS, cells were ﬁxed with 1% formaldehyde, followed by
ChIP assay using rabbit anti-FoxO1 antibody. The immunoprecipitates were subjected to semiquantitative PCR assay using primers ﬂanking the
conserved IRE DNA motif within the IL-1 promoter. After normalizing to input DNA controls, the amount of immunoprecipitated IL-1 promoter
DNA fragments was compared among different conditions. G: Effect of NF-B P50 knockdown on IL-1 promoter activity. RAW264.7 cells were
transfected with pHD386 encoding the IL-1 promoter–directed luciferase expression system in the presence or absence of FoxO1 production,
using the dual luciferase system. One subset of cells was cotransfected with siRNA that is targeted to the NF-B P50 subunit. Control cells were
transfected with control siRNA. After 24-h incubation, cells were harvested for the determination of luciferase activity. Data in A–G were from
three independent experiments. *P < 0.05 and **P < 0.001 vs. control. NS, not signiﬁcant.
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enhanced FoxO1 activity. This effect was mirrored by the
activation of NF-B in LPS- or palmitate-activated macro-
phages. Interestingly, we show that FoxO1 in concert with
activated NF-B produced a synergistic effect on the
induction of IL-1 overproduction in the presence of
inﬂammation. Together these results suggest that aug-
mented FoxO1 activity serves to amplify the action of
NF-B in stimulating macrophage IL-1 production under
inﬂammatory conditions (Fig. 8). This interpretation is
underpinned by three lines of evidence. First, the produc-
tive interaction between FoxO1 and IL-1 promoter DNA
was signiﬁcantly enhanced in the presence of P50 produc-
tion, correlating with the costimulatory effect of FoxO1
and P50 on IL-1 promoter activity in cultured macro-
phages. Second, siRNA-mediated knockdown of P50 sig-
niﬁcantly attenuated the ability of FoxO1 to stimulate
IL-1 expression in LPS-stimulated macrophages. Third,
the IL-1 promoter contains both FoxO1 and NF-B target
sites that are juxtaposed within the promoter-proximal
region of the Il1b gene in mice, rats, and humans (supple-
mental Fig. S2), implying an evolutionally conserved
mechanism for FoxO1 signaling through the NF-B path-
way in regulating proinﬂammatory cytokine IL-1 produc-
tion in macrophages in response to insulin resistance.
In conclusion, we characterized the Il1b gene as a
FoxO1 target, demonstrating that macrophage production
of IL-1 was stimulated by FoxO1 and inhibited by insulin.
Under insulin-resistant or inﬂammatory conditions, FoxO1
activity was augmented, because of an impaired ability of
insulin to phosphorylate FoxO1 and promote its nuclear
exclusion. This effect along with active NF-B contributed
to macrophage overproduction of IL-1. Although insulin
resistance is associated with low-grade inﬂammation in
obesity and type 2 diabetes, the underlying mechanism
remains obscure. Our data suggest that FoxO1 signaling
through NF-B plays a signiﬁcant role in coupling insulin
resistance to proinﬂammatory cytokine IL-1 production
in obesity and type 2 diabetes.
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